In an attempt to increase the in vivo cell killing effect of PARP inhibition on glioma cells we ideated (given the up-regulation of pro-survival signalling pathways in PTEN-deficient glioma cells) the co-treatment with an inhibitor of EGFR to disable pro-survival signals. Here, EGFR is linked to central nervous system cancer.